Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Dick's Sporting Goods cheers record quarter

(Sharecast News) - Shares in Dick's Sporting Goods jumped on Thursday, after bumper holiday season trading beat expectations. The retailer said fourth-quarter net sales jumped 7.8% to $3.88bn, or by 2.8% on a like-for-like basis, its largest-ever sales quarter.

Net income rose 26% to $296m, while earnings per diluted share increased 31% to $3.85.

Wall Street had been expecting revenues closer to $3.80bn and EPS of $3.35.

Lauren Hobart, chief executive, said it had been an "incredibly strong" quarter and holiday season.

She continued: "Even excluding the extra week, this was the largest sales quarter in the history of the company, and during the fourth quarter, we drove significant gross margin and EBT margin expansion."

Looking forward, Hobart forecast "another strong year. We plan to growth both our sales and earnings through positive comps, higher merchandise margin and productivity gains."

The retailer, which was founded in 1948 by Dick Stack, is forecasting 2024 EPS between $12.85 and $13.25, with net sales between $13bn and $13.13bn.

As at 1300 GMT, shares in Dick's had put on nearly 8% in pre-market trading.

In the year to 3 February 2023, Dick's posted net sales of $12.98bn, up 5% or 2.4% on a comparable store basis. Net income was largely flat, at $1.05bn, while EPS sparked 7% at $12.91.

The retailer also boosted its annualised dividend by 10% to $4.40 a share.

Share this article

Related Sharecast Articles

Hikma boosts injectables business with Xellia assets acquisition
(Sharecast News) - Hikma Pharmaceuticals said on Monday that it has agreed to buy parts of Xellia Pharmaceuticals, a Copenhagen-based specialty company focusing on providing anti-infective treatments and other critical care therapies, for up to $185m.
Ascential on track to hit targets this year
(Sharecast News) - Publishing, events and B2B consultancy group Ascential has said that trading is in line with expectations for the full year, helped by strong growth in marketing and fintech operations.
AstraZeneca's Imfinzi gets US approval for endometrial cancer patients
(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.
British Land CFO to join Kingfisher
(Sharecast News) - B&Q owner Kingfisher said it had appointed British Land chief financial officer Bhavesh Mistry to the same role at the home improvement company.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.